Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer
Source : https://www.thebreastonline.com/article/S0960-9776(22)00124-2/fulltext
The rising cost of cancer drug therapy threatens the long-term sustainability of Taiwan National Health Insurance. Cost savings can be achieved through various strategies, e.g., using smaller vial sizes, sharing...
Conclusion: The trastuzumab biosimilar combination regimen is cost-effective and offers significant drug cost savings in Taiwan.
-
Albert Dekker4yrWe use only biosimilars but savings are not that GREAT
-
Sarah Mougalian, Yale Cancer Center4yrI think this is where we are headed. Our academic medical center has switched to biosimilars for most biologics.
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer - Breast Cancer Research and Treatment
Source : https://link.springer.com/article/10.1007/s10549-022-06690-5
Purpose Abemaciclib, a CDK4 & 6 inhibitor, is indicated for advanced breast cancer treatment. Diarrhea is a frequently associated adverse event of abemaciclib. The study objective was to investigate if...
Conclusion: The results suggest that diarrhea incidence associated with abemaciclib was unrelated to timing of food intake, was predominantly low grade, of short duration and well managed with loperamide and dose modifications.
-
Albert Dekker4yrMy patients would generally not agree that diarrhea is low grade. No food association I believe it
-
Sarah Mougalian, Yale Cancer Center4yrFor the purposes of patient counseling, it does not appear that taking the medication with food or without food impacts incidence or severity of diarrhea.
CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin-proteasome pathway in ER + breast cancer - Clinical and Translational Oncology
Source : https://link.springer.com/article/10.1007/s12094-022-02881-0
Despite significant improvement in therapeutic development in the past decades, breast cancer remains a formidable cause of death for women worldwide. The hormone positive subtype (HR( +)) (also known as luminal...
Conclusion/Relevance: Our study suggests a novel link between CDK4/6 inhibitor and UPP pathway, adding to the potential mechanisms of their clinical efficacy in cancer.
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35917168/
Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4 and 6) are approved for the treatment of subsets of patients with hormone receptor positive (HR+) breast cancer (BC). In metastatic...
Implications for Practice: Three cyclin-dependent kinase 4 and 6 inhibitors (CDK4 and 6i) are approved for the treatment of hormone receptor positive (HR ) advanced or metastatic breast cancer. Readers will be presented with a summary of recent preclinical data outlining molecular mechanisms by which these agents exert their effects, with a...
Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer-A Literature Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35877254/
1 Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N3M5, Canada. 2 Department of Medicine, Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON M5S1A1, Canada. Free...
Conclusions: Classifying the risk category assists in deciding the treatment route and its optimal duration. Tailoring the breadth of ET hinges on a wide array of factors to be appraised for each individualized case, including weighing its benefits and harms.
-
Sarah Mougalian, Yale Cancer Center4yr#&gid=article-figures&pid=figure-2-uid-1
-
Sarah Mougalian, Yale Cancer Center4yr#&gid=article-figures&pid=figure-1-uid-0
Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer-A Literature Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35877254/
1 Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N3M5, Canada. 2 Department of Medicine, Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON M5S1A1, Canada. Free Show More